Physician profile
Michael Arcarese
NPI 1164452363
$10,447.33
in general payments reported to CMS, 2019-2025
48 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $1,169 · 2021: $802 · 2022: $1,842 · 2023: $1,693 · 2024: $1,606 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,920 · Education: $52.49 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,919.62 |
| Education | $52.49 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,058.71 | 2019-2025 | Watchman Flx, Bodyguardian, General - Therapies |
| Novartis Pharmaceuticals Corporation | $958.55 | 2019-2025 | |
| Amgen INC. | $807.09 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $706.34 | 2019-2025 | Farxiga, Andexxa, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.16 | 2019-2025 | Jardiance |
| Medtronic, INC. | $540.44 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Ffrangio |
| Janssen Pharmaceuticals, INC | $492.13 | 2019-2024 | Xarelto |
| Abbott Laboratories | $485.60 | 2020-2023 | Amplatzer Amulet |
| Pfizer INC. | $478.41 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $428.45 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $353.96 | 2021-2023 | Optimizer |
| Merck Sharp & Dohme LLC | $281.34 | 2022-2025 | Verquvo, Capvaxive |
| Scpharmaceuticals INC. | $252.85 | 2023-2025 | |
| Edwards Lifesciences Corporation | $247.08 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $242.53 | 2019-2024 | Evkeeza |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.87 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $236.38 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $232.21 | 2019-2025 | Uptravi, Opsumit |
| Medtronic Vascular, INC. | $179.34 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $133.28 | 2024-2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $118.09 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $116.03 | 2022-2025 | Assure Wcd |
| Amarin Pharma, INC. | $114.05 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $106.11 | 2022-2024 | Livalo |
| Baxter Healthcare | $105.65 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Shockwave Medical, INC | $98.66 | 2025 | |
| Esperion Therapeutics, INC. | $90.34 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $89.01 | 2019-2024 | |
| Cardiovascular Systems INC. | $85.34 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $79.93 | 2023-2024 | Inpefa |
| Cardiva Medical, INC. | $58.30 | 2019-2025 | Optowire |
| Azurity Pharmaceuticals, INC. | $57.62 | 2024-2025 | Edarbi, Edarbyclor |
| Livanova USA, INC. | $54.80 | 2020-2021 | |
| Abiomed | $43.27 | 2024-2025 | Impella |
| Heartflow, INC. | $42.35 | 2025 | |
| Chiesi USA, INC. | $32.12 | 2020 | |
| Gilead Sciences, INC. | $28.60 | 2019 | |
| Portola Pharmaceuticals, LLC | $27.99 | 2019 | |
| Genzyme Corporation | $26.57 | 2024 | |
| Atricure, INC. | $23.85 | 2019 | |
| Mannkind Corporation | $21.30 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $20.66 | 2023 | Arcalyst |
| Irhythm Technologies, INC. | $20.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.17 | 2022 | |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Welch Allyn | $18.00 | 2019 | |
| Nuwellis, INC. | $17.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Arcarese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.